Roberto Romero1,2,3,4, Piya Chaemsaithong1,5, Adi L Tarca1,5, Steven J Korzeniewski1,3,5, Eli Maymon1,5, Percy Pacora1,5, Bogdan Panaitescu1,5, Noppadol Chaiyasit1,5, Zhong Dong1,5, Offer Erez1,5, Sonia S Hassan1,5, Tinnakorn Chaiworapongsa1,5. 1. a Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research , Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/DHHS , Bethesda , MD, and Detroit, MI , USA. 2. b Department of Obstetrics and Gynecology , University of Michigan , Ann Arbor , MI , USA. 3. c Department of Epidemiology and Biostatistics , Michigan State University , East Lansing , MI , USA. 4. d Center for Molecular Medicine and Genetics , Wayne State University , Detroit , MI , USA. 5. e Department of Obstetrics and Gynecology , Wayne State University School of Medicine , Detroit , MI , USA.
Abstract
OBJECTIVE: The objectives of this study were to determine (1) the longitudinal profile of plasma soluble ST2 (sST2) concentrations in patients with preeclampsia and those with uncomplicated pregnancies; (2) whether the changes in sST2 occur prior to the diagnosis of preeclampsia; and (3) the longitudinal sST2 profile of women with early or late preeclampsia. MATERIALS AND METHODS: This longitudinal nested case-control study included singleton pregnancies in the following groups: (1) uncomplicated pregnancies (n = 160); and (2) those complicated by early (<34 weeks, n = 9) and late (≥34 weeks, n = 31) preeclampsia. sST2 concentrations were determined by enzyme-linked immunosorbent assays. Mixed-effects models were used for the longitudinal analysis. RESULTS: (1) Plasma sST2 concentration profiles across gestation differed significantly among cases and controls (p < 0.0001); (2) women with early preeclampsia had higher mean sST2 concentrations than controls at >22 weeks of gestation; cases with late preeclampsia had higher mean concentrations at >33 weeks of gestation (both p < 0.05); and (3) these changes started approximately 6 weeks prior to clinical diagnosis. CONCLUSIONS: Maternal plasma sST2 concentrations are elevated 6 weeks prior to the clinical diagnosis of preeclampsia. An increase in the maternal plasma concentration of sST2 may contribute to an exaggerated intravascular inflammatory response and/or the Th1/Th2 imbalance in some cases.
OBJECTIVE: The objectives of this study were to determine (1) the longitudinal profile of plasma soluble ST2 (sST2) concentrations in patients with preeclampsia and those with uncomplicated pregnancies; (2) whether the changes in sST2 occur prior to the diagnosis of preeclampsia; and (3) the longitudinal sST2 profile of women with early or late preeclampsia. MATERIALS AND METHODS: This longitudinal nested case-control study included singleton pregnancies in the following groups: (1) uncomplicated pregnancies (n = 160); and (2) those complicated by early (<34 weeks, n = 9) and late (≥34 weeks, n = 31) preeclampsia. sST2 concentrations were determined by enzyme-linked immunosorbent assays. Mixed-effects models were used for the longitudinal analysis. RESULTS: (1) Plasma sST2 concentration profiles across gestation differed significantly among cases and controls (p < 0.0001); (2) women with early preeclampsia had higher mean sST2 concentrations than controls at >22 weeks of gestation; cases with late preeclampsia had higher mean concentrations at >33 weeks of gestation (both p < 0.05); and (3) these changes started approximately 6 weeks prior to clinical diagnosis. CONCLUSIONS: Maternal plasma sST2 concentrations are elevated 6 weeks prior to the clinical diagnosis of preeclampsia. An increase in the maternal plasma concentration of sST2 may contribute to an exaggerated intravascular inflammatory response and/or the Th1/Th2 imbalance in some cases.
Authors: Neil O'Gorman; David Wright; Argyro Syngelaki; Ranjit Akolekar; Alan Wright; Leona C Poon; Kypros H Nicolaides Journal: Am J Obstet Gynecol Date: 2015-08-19 Impact factor: 8.661
Authors: Jennifer H Southcombe; Samantha J Benton; Yuxiang Hu; Peter von Dadelszen; Tim Child; James V Snider; Christopher W G Redman; Ian L Sargent; Ingrid Granne Journal: Pregnancy Hypertens Date: 2013-03-06 Impact factor: 2.899
Authors: Svitlana Demyanets; Christoph Kaun; Richard Pentz; Konstantin A Krychtiuk; Sabine Rauscher; Stefan Pfaffenberger; Andreas Zuckermann; Arezu Aliabadi; Marion Gröger; Gerald Maurer; Kurt Huber; Johann Wojta Journal: J Mol Cell Cardiol Date: 2013-04-06 Impact factor: 5.000
Authors: Ina A Stelzer; Mohammad S Ghaemi; Xiaoyuan Han; Kazuo Ando; Julien J Hédou; Dorien Feyaerts; Laura S Peterson; Kristen K Rumer; Eileen S Tsai; Edward A Ganio; Dyani K Gaudillière; Amy S Tsai; Benjamin Choisy; Lea P Gaigne; Franck Verdonk; Danielle Jacobsen; Sonia Gavasso; Gavin M Traber; Mathew Ellenberger; Natalie Stanley; Martin Becker; Anthony Culos; Ramin Fallahzadeh; Ronald J Wong; Gary L Darmstadt; Maurice L Druzin; Virginia D Winn; Ronald S Gibbs; Xuefeng B Ling; Karl Sylvester; Brendan Carvalho; Michael P Snyder; Gary M Shaw; David K Stevenson; Kévin Contrepois; Martin S Angst; Nima Aghaeepour; Brice Gaudillière Journal: Sci Transl Med Date: 2021-05-05 Impact factor: 17.956